Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMT-NK plus pembrolizumab vs pembrolizumab in advanced biliary tract cancer
KCT0007476Phase 3Recruiting
- Sponsor
- SMT bio Co., Ltd.
- Start
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in biliary cancer comparing SMT-NK plus pembrolizumab with Pembrolizumab monotherapy with placebo (2 arms). Started Jun 2022; status: recruiting.
02
Drugs
SMT-NKpembrolizumab
03
Conditions
biliary cancer
Beyond the preview
Go deeper on KCT0007476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007476.